About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
Previous Close | $11.36 | Open | |
Volume | Market Cap | 1.588B | |
Yield | Last Dividend |
Global Hemophilia Gene Therapy Market by... | 03/05/21 |
Latest Research Study on Global Hemophilia Gene Therapy Market published by Research N Reports, offers a detailed overview of the factors influencing ... |
mRNA Vaccines & Therapeutics Market Swot... | 03/03/21 |
Latest Market intelligence report released by HTF MI with title "Global mRNA Vaccines & Therapeutics Market Growth 2021-2026" is designed covering mic... |
Sangamo Therapeutics Reports Recent Busi... | 02/24/21 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year ... |
Sangamo Therapeutics Announces Participa... | 02/18/21 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be part... |
Sangamo Therapeutics Announces Fourth Qu... | 02/17/21 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has schedul... |
Sangamo Therapeutics Appoints Rob Schott... | 02/01/21 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schot... |
Study Describes New Way to Place CRISPR/... | 01/07/21 |
Clusters of regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 nuclease (Cas9) is an innovative genome editing tool ... |
Sangamo Therapeutics to Present at the 3... | 01/05/21 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present... |
The Daily Biotech Pulse: FDA Nod For Amp... | 12/29/20 |
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Acl... |
Global Gene Therapy Market Report 2020-2... | 12/17/20 |
DUBLIN, Dec. 17, 2020 /PRNewswire/ -- The "Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAnd... |
According to Latest Report on mRNA Vacci... | 12/11/20 |
The demand for mRNA Vaccine Market 2020 is anticipated to be high for the next few years. By considering this demand we provide latest mRNA Vaccine Ma... |
Pfizer and Sangamo Announce Updated Phas... | 12/07/20 |
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, toda... |
Analysts Expect Sangamo Therapeutics Inc... | 10/20/20 |
Analysts expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to post sales of $28.63 million for the current fiscal quarter, Zacks Investment Research repor... |
Sangamo Therapeutics Appoints Kenneth Hi... | 09/11/20 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenne... |
Sangamo Therapeutics Announces Participa... | 09/02/20 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present... |
How Much Is Sangamo Therapeutics, Inc. (... | 09/01/20 |
Sandy Macrae became the CEO of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in 2016, and we think it's a good time to look??? |
The Daily Biotech Pulse: Novavax Vaccine... | 08/07/20 |
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVI... |
Sangamo Therapeutics Reports Business Hi... | 08/05/20 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial... |
Collaborating to explore new gene regula... | 07/30/20 |
Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases. |
Sangamo Therapeutics Announces Second Qu... | 07/29/20 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has schedul... |
Sangamo Therapeutics Announces Participa... | 05/29/20 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present... |
Sangamo Therapeutics Announces Participa... | 05/12/20 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present... |
Sangamo Therapeutics (SGMO) Reports Q1 L... | 05/11/20 |
Sangamo (SGMO) delivered earnings and revenue surprises of -60.87% and -57.78%, respectively, for the quarter ended March 2020. Do the numbers hold cl... |
Sangamo Therapeutics Reports Business Hi... | 05/11/20 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial ... |
Is Sangamo Therapeutics (SGMO) Stock Out... | 05/05/20 |
Is (SGMO) Outperforming Other Medical Stocks This Year? |
Sangamo Therapeutics Announces First Qua... | 05/04/20 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has schedul... |
Sangamo Therapeutics Announces Presentat... | 04/28/20 |
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several ab... |
Mogrify strikes deal with US biopharma S... | 04/27/20 |
The companies have announced a collaboration and licence agreement. |
Mogrify and Sangamo announce collaborati... | 04/21/20 |
CAMBRIDGE, England & BRISBANE, Calif.--(BUSINESS WIRE)--Mogrify Ltd (Mogrify??), a UK company aiming to transform the development of cell therapies by... |
Sangamo Therapeutics and Biogen Announce... | 02/27/20 |
The partnership would focus on developing treatments for neurological diseases. |
Hold rating | 01/06/21 |
Stifel initiates coverage with Hold rating and announces Price Target of $16.00 |
Buy rating | 12/16/20 |
and announces Price Target of $25.00 |
Date | 2021-02-24 (AMC) | Est. (EPS/Rev.) | ($0.21)/ 32.15M |
Actual (EPS/Rev.) | $-0.29/ $25.80 M | EPS (TTM) | 0 |
Total Revenue | $1.3B | Total Liabilities | $2.1B |
Cost of Revenue | $2.5B | Total cash flow | $3.2 |
Total Assets | $29.98B |
% Insider | 12.52% | % Institutional | 76.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Service Name | Trader | % Success | |
---|---|---|---|
Swingtrades | R. belegger | 83.00 % | Follow |
Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
10 Picks Every Day (90 Days) | The Grim Contango | 77.00 % | Subscribe |
Stocks and Options | Dr. Rao | 50.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.